Infarct size as assessed by peak enzyme levels is reduced in patients who are using angiotensin-converting enzyme inhibitors at the onset of infarction

Clinical Drug Investigation

Volumn 20, Issue 6, 2000, Pages 415-423

  Landmark, Knud ^a,b   Aursnes, Ivar ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CREATINE KINASE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LACTATE DEHYDROGENASE; LISINOPRIL; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0034545736     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020060-00004     Document Type: Article

References (58)

1. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
2. The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
3. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
4. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
5. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
6. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
7. Preservation of ischemic myocardium by a new convening enzyme inhibitor, enalaprilic acid, in acute myocardial infarction
8. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts
9. Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in the closed chest pig model
10. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist
11. Beneficial effect of captopril against ischaemia-reperfusion injury in isolated guinea pig hearts
12. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: Role of bradykinin
13. Does captopril treatment before thrombolysis in acute myocardial infarction attenuate reperfusion damage? Short-term and long-term effects
14. Captopril in acute myocardial infarction: Beneficial effects on infarct size and arrhythmias
15. Ventricular arrhythmias in acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril
16. Influence of prior ACE inhibitor therapy on morbidity and mortality following acute myocardial infarction
17. Enzyme tests in the evaluation of thrombolysis in acute myocardial infarction
18. Infarct size as estimated from peak creatine kinase and lactate dehydrogenase is probably reduced in patients using calcium antagonists at the onset of symptoms
19. Comparison of acute myocardial infarct size to two-year mortality in patients <65 to those >65 years of age
20. Comparisons of ASAT, CK, CK-MB, and LD for estimation of acute myocardial infarct size in man
21. Assessment of myocardial damage in patients with acute myocardial infarction by serial measurement of serum alfa-hydroxybutyrate dehydrogenase levels
22. Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size
23. The renin-aldosterone-angiotensin system and the clinical course of acute myocardial infarction
24. Renin and the complications of acute myocardial infarction
25. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure
26. Inhibition of ACE/kininase-II, acute myocardial infarction, and survival
27. Angiotensin- and norepinephrine-induced myocardial lesions: Experimental and clinical studies in rabbits and man
28. Effect of angiotensin-induced hypertension on rat coronary arteries and myocardium
29. The use of ACE-inhibitors in hypertension
30. Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors
31. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
32. Influence of the angiotensin system on endothelial and smooth muscle cell migration
33. Angiotensin II induced smooth muscle cell proliferation in the normal and injured rat arterial wall
34. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II
35. Regulation of cell proliferation and growth by angiotensin II
36. Angiotensin II signalling pathways in cardiac fibroblasts: Conventional versus novel mechanisms in mediating cardiac growth and function
37. Suppressive effect of captopril on platelet aggregation in essential hypertension
38. Treatment of hypertension with captopril: Preservation of regional blood flow and reduced platelet aggregation
39. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and the fibrinolytic function
40. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
41. Effect of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
42. Ramiprilat increases bradykinin outflow from isolated hearts of rat
43. Converting enzyme inhibitors in cardiovascular therapy: Current status and future potential
44. ACE inhibition, endothelial function and coronary artery lesions - Role of kinins and nitric oxide
45. Endothelial protection by converting enzyme inhibitors
46. Endothelium-dependent vasodilation is augmented by angiotensin converting enzyme inhibitors in healthy volunteers
47. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversal Endothelial Dysfunction) Study
48. Effect of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction
49. Mechanisms by which quinapril improves vascular function in coronary artery disease
50. Concentration-dependent protection by captopril against ischemia-reperfusion injury in the isolated rat heart
51. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?
52. Myocardial ischemia, reperfusion and free radical injury
53. Infarct size is reduced and the frequency of non-Q-wave myocardial infarctions is increased in patients using aspirin at the onset of symptoms
54. Translation of clinical trials into practice: A European population-based study of the use of thrombolysis for acute myocardial infarction
55. Relation of peak creatine kinase levels during acute myocardial infarction to presence or absence of previous manifestations of myocardial ischemia (angina pectoris or healed myocardial infarction)
56. Coronary collateral circulation: Clinical significance and influence on survival in patients with coronary artery occlusion
57. Influence of coronary collateral vessels on myocardial infarct size in humans: Results of phase I thrombolysis in myocardial infarction (TIMI) trial
58. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction